Abstracts tagged "Connective tissue diseases and interstitial lung disease"

Abstract Number: 2902 • 2019 ACR/ARP Annual Meeting
The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease
Christopher Mesa¹, Snehaja Yadlapati ¹ and Myriam Guevara ², ¹Louisiana State University Health Science Center, New Orleans, LA, ²Louisiana State University School of Medicine, New Orleans
Background/Purpose: Interstitial Lung Disease (ILD) is the most common lung manifestation in Connective Tissue Diseases (CTD). It is present in most types of CTD, such…
Abstract Number: 1311 • 2018 ACR/ARHP Annual Meeting
A Multidisciplinary Cohort of Patients with Interstitial Pneumonia with Autoimmune Features
Gabriel Schroeder¹, April Barnado², Narender Annapureddy³, Rosemarie Dudenhofer⁴, Leslie Crofford² and Erin Wilfong⁵, ¹Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, ²Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁵Division of Rheumatology and Immunology, Vanderbilt Unversity Medical Center, Nashville, TN
Background/Purpose: Interstitial Lung Disease (ILD) remains a significant diagnostic and therapeutic challenge, especially for patients who do not meet criteria for a connective tissue disease…
Abstract Number: 1312 • 2018 ACR/ARHP Annual Meeting
Interstitial Pneumonia with Autoimmune Features (IPAF)-Nsip: Hurdles to Reclassification of Overlapping Ilds
Amaka Odonwodo¹ and Aman Pande², ¹Internal Medicine, Cleveland Clinic, Cleveland, OH, ²Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH
Background/Purpose: Interstitial lung disease (ILD) may occur in the presence of autoimmune elements without meeting criteria for a distinctive Connective Tissue Disease. The European Respiratory…
Abstract Number: 1172 • 2017 ACR/ARHP Annual Meeting
Utility of Interstitial Pneumonia with Autoimmune Features (IPAF) Proposed Criteria in the Classification of Patients with CTD-Associated Interstitial Lung Disease in a Single Centre
Fredeswinda I. Romero-Bueno¹, Ana Sofía Pozo², Maria Jesus Rodriguez-Nieto³, Maria José Martinez-Becerra⁴, Gabriel Herrero-Beaumont⁵ and Olga Sanchez-Pernaute¹, ¹Section for Autoimmune Diseases, Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ²Faculty of Medicine, Autonoma University of Madrid, Madrid, Spain, ³Pulmonary Medicine, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ⁴Immunology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ⁵Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain
Background/Purpose: The term interstitial pneumonia with autoimmune features (IPAF) has recently been proposed to identify those patients with ILD and clinical and/or serological autoimmune manifestations…
Abstract Number: 1181 • 2017 ACR/ARHP Annual Meeting
Serum KL-6 Level Reflects Severity of Interstitial Lung Disease Associated with Connective Tissue Disease
Jeong Seok Lee¹, Eun Young Lee², Jin Kyun Park³, Eun Bong Lee² and Yeong Wook Song⁴, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ³Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), ⁴Department of Molecular medicine and biopharmaceutical science, Seoul National University, Seoul, Korea, Republic of (South)
Background/Purpose: Measuring severity of interstitial lung disease (ILD) usually depends on the extent or pattern of imaging findings on computed tomography (CT) and the parameters…
Abstract Number: 1876 • 2017 ACR/ARHP Annual Meeting
A Non-Invasive Ultrasound Surface Wave Elastography Technique for Assessing Interstitial Lung Disease
Thomas Osborn¹, Xiaoming Zhang², Sanjay Kalra³, Boran Zhou⁴ and Brian Bartholmai⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic college of Medicine, Rochester, MN, ³Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁴Radiology, Mayo Clinic, Rochester, MN, ⁵Thoracic Radiology, Mayo Clinic, Rochester, MN
Background/Purpose: Surface wave elastography is an ultrasound based noninvasive technique to measure tissue viscoelasticity (“stiffness”). Preliminary studies in assessing scleroderma associated skin thickening have been…
Abstract Number: 2116 • 2017 ACR/ARHP Annual Meeting
Evaluation of Connective Tissue Diseases in Patients Presenting with Interstitial Lung Disease in a Referral Center in Santiago, Chile
Verónica Wolff^1,2, Matías Florenzano¹, Angela Rivera³, Carolina Cuellar⁴, Juan Maya⁵, Mauricio Salinas^1,6, Cristian Ibarra¹, Angélica Bello⁷ and Daniela Soto⁸, ¹Rheumatic Lung diseases Unit, Instituto Nacional del Tórax, Santiago, Chile, ²Rheumatology Unit, Hospital del Salvador, Facultad de Medicina, Universidad de Chile, Santiago, Chile, ³Rheumatology Unit, Hospital Del Salvador, Facultad de Medicina, Universidad de Chile, Santiago, Chile, ⁴Rheumatology unit, Hospital Del Salvador, Facultad de Medicina, Universidad de Chile, SANTIAGO, Chile, ⁵Rheumatology Unit, Hospital del Salvador. Facultad de Medicina. Universidad de Chile, Santiago, Chile, ⁶Facultad de Medicina, Universidad de Chile, Santiago, Chile, ⁷Instituto Nacional del Tórax - Universidad de Chile, SANTIAGO, Chile, ⁸Instituto Nacional del Tórax - Universidad de Chile, Santiago, Chile
Background/Purpose: Connective tissue diseases (CTDs) are systemic autoimmune disorders that can compromise the lung. Interstitial lung disease (ILD) is one of the mayor forms of…
Abstract Number: 275 • 2015 ACR/ARHP Annual Meeting
A Comparison of the Clinical Features and Natural History of Autoimmune Interstitial Lung Disease Vs. Idiopathic Pulmonary Fibrosis
Sandra Chartrand¹, Lina Peykova², Jeffery J. Swigris³ and Aryeh Fischer⁴, ¹Université de Montréal, Montreal, QC, Canada, ²Rheumatology, National Jewish Health, Denver, CO, ³National Jewish Health, Denver, CO, ⁴University of Colorado School of Medicine, Aurora, CO
Background/Purpose: We compared clinical features, longitudinal pulmonary physiology, and survival among 3 groups of patients evaluated at our center between February 2008 to August 2014:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].